1) Hirai K, Ishiko O, Sumi T, et al : Indifference and resignation of Japanese women toward urinary incontinence. Int J Gynecol Obstet 75 : 89─91, 2001
2) Nilsson M, Lalos A and Lalos O : The impact of female urinary incontinence and urgency on quality of life and partner relationship. Neurourol Urodynam 28 : 976─981, 2009
3) Coyne KS, Wein AJ, Tubaro A, et al : The burden of lower urinary tract symptoms evaluating the effect of LUTS on health-related quality of life, anxiety and depression : EpiLUTS. BJU Int 103 : 4─11, 2009
4) Homma Y, Paick JS, Lee JG, et al : Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder : a randomized, placebo-controlled trial. BJU Int 92 : 741─747, 2003
5) Homma Y and Yamaguchi O : A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 16 : 499─506, 2009
6) 久保田伸稔, 福地 清, 山中 滋, 他 : 過活動膀胱患者におけるイミダフェナシンの安全性および有効性に関する製造販売後調査. 泌外30 : 1665─1681, 2017
7) Shimada M, Inoue K, Okumura T, et al : Efficacy and safety of imidafenacin in female patients with urge and mixed urinary incontinence. Hinyokika Kiyo 57 : 1─6, 2011
8) Mitsuhashi K and Matsuda H : Investigation of efficacy and safety of imidafenacin on overactive bladder. J New Rem & Clin 60 : 105─111, 2011
9) Hsiao SM, Chang TC, Wu WY, et al : Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 37 : 1084─1091, 2011
10) Aizawa N, Ito H, Sugiyama R, et al : Selective inhibitory effect of imidafenacin and 5-hydroxymethyl tolterodine on capsaicin sensitive C fibers of the primary bladder mechanosensitive afferent nerves in the rat. J Urol 193 : 1423─1432, 2015